patient | Page 58 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

patient

Women and PNH

During this webinar, Dr. Jamile Shammo from Rush University Medical Center, discusses PNH and special concerns for women. Topics discussed in the webinar are: puberty, birth control, pregnancy, menopause and hysterectomy.

Secondary MDS/AML in Women After Chemotherapy

Kathleen Moore, MD is Director, Oklahoma TSET Phase I Program; Associate Professor, Section of Gynecologic Oncology and is an associate professor in the section of gynecologic oncology and serves as the director of the Oklahoma TSET Phase I Clinical Trials Program, the state’s only phase I clinical trials program. She is the Jim and Christy Everest Endowed Chair in Cancer Research as well as the director of the gynecologic oncology fellowship program.

Moderate Aplastic Anemia: A Treatment Dilemma

Swapna Thota, MD joined Roswell Park in 2017 where she specializes in caring for patients with acute leukemias, MDS and other blood cancers. She holds a dual appointment as Assistant Professor of Oncology at Roswell Park Comprehensive Cancer Center and Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo.  Dr. Thota's research focuses on hematologic malignancies, especially on novel drug development to improve outcomes in patients with blood cancers. 

Chronic Kidney Disease and PNH

Dr. Ramy Hanna is an Assistant Clinical Professor of Medicine and Nephrology at the University of California Irvine UCI-Health. He is a clinician-educator who works at the intersection of patient education and research, participating in ongoing research into diseases of the kidneys (nephrology) as it relates to complement disorders such as PNH. Dr. Hanna is focused on working with underserved communities and the expanding field of Artificial Intelligence/Machine Learned related to improving the diagnostic process and treatment outcomes for patients.